Raltegravir central nervous system tolerability in clinical practice
2012; Lippincott Williams & Wilkins; Volume: 26; Issue: 18 Linguagem: Inglês
10.1097/qad.0b013e32835aa141
ISSN1473-5571
AutoresGiordano Madeddu, Barbara Menzaghi, Elena Ricci, Laura Carenzi, Canio Martinelli, Antonio Di Biagio, Giustino Parruti, Giancarlo Orofino, María Stella Mura, Paolo Bonfanti,
Tópico(s)HIV-related health complications and treatments
ResumoCentral nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice.
Referência(s)